quartr
LAURUSLABS: Record quarterly growth driven by CDMO and Affordable Medicines, with margins and CapEx rising
Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO and 10% rise in Affordable Medicines. Margins expanded, CapEx guidance doubled to INR 2,000 crore, and the business remains well-diversified with strong global demand and robust outlook.Based on Laurus Labs Ltd. [LAURUSLABS…